Enzo Biochem, Inc. (‘Enzo’) operates as a life sciences company.
The primary business of Enzo is conducted through its Life Sciences division (‘Enzo Life Sciences’), which focuses on labeling and detection technologies from DNA to whole cell analysis, including a comprehensive portfolio of thousands of high-quality products, including antibodies, genomic probes, assays, biochemicals, and proteins. The company’s proprietary products and technologies play central roles in translational research a...
Enzo Biochem, Inc. (‘Enzo’) operates as a life sciences company.
The primary business of Enzo is conducted through its Life Sciences division (‘Enzo Life Sciences’), which focuses on labeling and detection technologies from DNA to whole cell analysis, including a comprehensive portfolio of thousands of high-quality products, including antibodies, genomic probes, assays, biochemicals, and proteins. The company’s proprietary products and technologies play central roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. The company monetizes its technology primarily via sales through the company’s global distribution network and licensing. Enzo Life Sciences is operated through the company’s wholly-owned subsidiary, Enzo Life Sciences, Inc., and its wholly-owned foreign subsidiaries.
In prior years, the company also had a clinical lab business, operated as Enzo Clinical Labs, Inc. (‘Clinical Labs’). In July 2023, the company sold certain assets and assigned certain liabilities of Clinical Labs to Laboratory Corporation of America Holdings pursuant to an Asset Purchase Agreement dated March 16, 2023, as amended July 3, 2023 (‘APA’).
Strategy
The company is composed of scientists, passionate about empowering other scientists to achieve innovations in research, drug discovery and development, and diagnostic solutions. The company is driven to help its customers be the agents of change that make the world a healthier place. The company is focused on providing exceptional life science products and services, backed by expert scientific support, and delivered with an elevated customer experience. In Enzo Life Sciences, the company commercializes new products and maintains availability of its deep product portfolio via its global marketing and sales distribution infrastructure.
The company leverages its years of innovation and technical expertise to support research, drug discovery and development, and diagnostic solutions through its core technology platforms.
Enzo operates, under its own name, worldwide through wholly-owned subsidiaries in the U.S., Switzerland, Benelux, Germany, and the UK, with a branch office in France and a network of third-party distributors in other significant markets worldwide. The company’s comprehensive product portfolio allows it to deliver integrated solutions to basic researchers, drug developers, and clinical researchers around the globe. The company’s research provides solutions in all key research areas, including: Genomics, Cell Biology, Biomarker Detection, and in a multitude of applied research markets, including: Spatial Biology, Cell and Gene Therapy, Bioprocess, Personal Care, Cancer Research, and Neuroscience.
In addition, with in-house U.S. manufacturing, direct sales offices in six countries, two logistics centers in the U.S. and Europe, and a network of over 45 distributors, Enzo is able to deliver the company’s products to its customers when they need them – often shipping within 24 to 48 hours.
Markets
Life Sciences – Drug Discovery, Development, and Diagnostics
The company is a global manufacturer of cost-effective, high-quality solutions to enable drug discovery, development, and translational research workflows supported by Good Manufacturing Practices (‘GMP’) manufacturing. Enzo participates in this broad market that includes technology platforms and products used by a wide array of customer types, including: academic researchers, clinical researchers, biotechnology and pharmaceutical companies, and diagnostic manufacturers. The company’s broad spectrum of products, such as labels, dyes, antibodies, genomic probes, immunoassays, biochemicals, and proteins, are used to label, detect, and visualize a biological target of interest in drug discovery exploration and drug development process development. Enzo leverages its differentiated capabilities in labeling and detection, assay kitting and validations, and integrated manufacturing to serve as a ‘one-stop shop’ for thousands of reagents that are critical to workflows across various technologies and applications, validated by over 160,000 scientific publications.
Patents
During fiscal years 2024 and 2023, the company was issued twenty-five patents and seven patents, respectively. When developing technology and launching new product platforms, the company considers patent protection for certain core technology platforms, as well as for ancillary technologies that support these platforms.
There is one case that was originally brought by the company that is still pending in the Court. In that case, Enzo alleges patent infringement of the ’197 patent against Becton Dickinson defendants.
At the end of fiscal 2024, the company owned a portfolio of patents relating to products, methods, and procedures resulting from the company’s internal or sponsored research projects. The company also relies on its trade secrets and continuing technological innovation.
The company’s intellectual property portfolio can be divided into patents that provide claims in primary categories, as described below:
Dye Chemistry
The company has done extensive work in developing patents and proprietary technologies for dyes useful in the detection of cellular organelles and dyes to detect the status of cells in terms of enzyme activity, oxidation, or health status. Enzo also has patents directed to proprietary dyes and quenchers that may be used to label and detect nucleic acids.
Core Technologies for Gene, Protein, Cell, and Tissue Analysis
The company has developed a portfolio of patents and proprietary technologies for a variety of research, diagnostic, and therapeutic applications. Technology platforms and products are developed and offered for use by its customers to label, detect, and visualize their target of interest.
Enzo has patent coverage for a unique highly sensitive method of making probes to detect RNA transcripts in cells or tissue, which may be used to detect disease. The company also has patent coverage for the attachment of an oligonucleic acid to a monoclonal antibody, which can further enhance detection of a specific target.
Gene Analysis Technology
All gene-based testing is premised on the knowledge that DNA forms a double helix consisting of two complementary strands that match and bind to each other. If a complementary piece of DNA (a probe) is introduced into a sample containing its matching DNA, it will bind to, or hybridize, to form a double helix with that DNA.
Historically, the company has swiftly and decisively responded to challenges within the life sciences market. As the market demanded methods to specifically and accurately identify disease targets, Enzo has provided tools to meet such needs. Whether it was its various gene analysis solutions for HPV detection or broader platforms for the labeling, detection, amplification, and analysis of nucleic acids, Enzo has translated the company’s technological know-how into market-relevant tools for solving customers’ technological challenges.
The company has recently expanded in this area with its AMPIVIEW in situ hybridization technology, thereby creating potential opportunities with various drug development segments.
Amplification
In the early stages of infection, a pathogen may be present in very small amounts and consequently may be difficult to detect. Using DNA amplification, samples can be treated to cause a pathogen’s DNA to be replicated, or amplified, to detectable levels. The company has developed patents for an amplification process for multicopy production of nucleic acids, as well as proprietary techniques for amplifying the signals of the company’s probes to further improve sensitivity. The company’s amplification technologies are particularly useful for the early detection of very small amounts of target DNA.
Non-Radioactive Labeling and Detection for Gene Analysis
Traditionally, nucleic acid probes were labeled with radioactive isotopes. However, radioactively labeled probes have a number of shortcomings; they are unstable and consequently have a limited shelf life, and they are potentially hazardous, resulting in restrictive licensing requirements and safety precautions for preparation, use, and disposal. Finally, radioactive components are expensive. The company’s technologies permit gene analysis and avoid the problems associated with radioactively labeled probes, and are adaptable to a wide variety of formats.
Formats
There are various processes, or formats, for performing probe-based tests. In certain formats, the probe is introduced to a target sample affixed to a solid matrix; in others, the probe is combined with the sample in solution (homogeneous assay). Solid matrix assays include: in situ assays in which the probe reaction takes place directly on a microscope slide; dot blot assays in which the target DNA is fixed to a membrane; and microplate and microarray assays in which the DNA is fixed on a solid surface, and the reaction can be quantified by instrumentation.
Research and Development
In the fiscal year ended July 31, 2024, the company incurred costs of approximately $2.6 million for research and development activities.
Sales and Marketing
The company’s sales and marketing strategy is to sell its life sciences products through: direct sales to end-users under the Enzo Life Sciences name, with direct recognition to its acquired brands; direct sales to end-users under the Axxora electronic marketplace name; supply agreements with manufacturers; and distributors in major geographic markets. Axxora is a proven distribution platform for original manufacturers of innovative research reagents. Researchers use the company’s unique marketplace to connect with over 45 specialty manufacturers and gain access to over 200,000 products. The company operates with an understanding of local markets and a well-functioning distribution network system across the globe. The company has a worldwide customer support group operated by scientists to consult with its broad and deep customer base that is situated in dozens of countries around the globe. Scientists around the world who recognize the brands Alexis, Assay Designs, Biomol, Enzo, and Stressgen now receive products directly from Enzo Life Sciences, and the company is recognized for innovative high-quality products, supported directly by its qualified global technical staff. The company’s direct marketing and sales network includes fully-owned subsidiaries in the U.S., Switzerland, Germany, Benelux, and the UK, a branch office in France, and a network of third-party distributors in most other significant markets worldwide.
Regulations
Privacy, security, and breach notification requirements under the Health Insurance Portability and Accountability Act (‘HIPAA’) apply to the company’s continuing operations in a limited manner due to Enzo providing a self-insured health plan to eligible employees. With respect to the company’s discontinued operations, the company also needs to continuously ensure that there are mechanisms in place to safeguard the privacy of protected health information (‘PHI’) that is transmitted or maintained in any format (e.g., oral, written, or electronic). The company is required to maintain numerous policies and procedures in order to comply with these requirements.
In addition, to comply with the HIPAA security regulations in particular, the company must ensure the confidentiality, integrity, and availability of all electronic PHI (‘EPHI’) that it creates, receives, maintains, or transmits. The security regulations strongly emphasize that the company must periodically conduct an accurate and thorough assessment of the potential risks and vulnerabilities to the confidentiality, integrity, and availability of its EPHI and then document its response to the various security regulations on the basis of that assessment.
Through the company’s agreements with its third-party credit card processors, the company is subject to payment card association operating rules, including the Payment Card Industry Data Security Standard (‘PCI-DSS’), which governs a variety of areas, including how consumers and customers may use their cards, the security features of cards, security standards for processing, data security, and allocation of liability for certain acts or omissions, including liability in the event of a data breach.
The company is subject to the U.S. Federal Occupational Safety and Health Administration’s (‘OSHA’s’) requirement that employers using hazardous chemicals communicate the properties and hazards presented by those chemicals to their employees.
The company’s business is and will continue to be subject to regulation under various state and federal environmental, safety, and health laws, including the Occupational Safety and Health Act, the Resource Conservation and Recovery Act, and the Atomic Energy Act or their state law analogs.
The company is subject to inspection and market surveillance by the U.S. Food and Drug Administration (‘the FDA’) to determine compliance with regulatory requirements. The company has employees to expedite the preparation and filing of documentation necessary for FDA clearances, authorizations, and approvals, as well as patent issuances and licensing agreements.
History
Enzo Biochem, Inc. was founded in 1976. The company was incorporated in 1976.
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
